Profile
Ed Gemo is Chief Information Officer & Senior Vice President of Turning Point Therapeutics, Inc. In the past Mr. Gemo held the position of Chief Information & Security Officer, VP at Halozyme Therapeutics, Inc., Chief Information Officer & Vice President for Onyx Pharmaceuticals, Inc. and Chief Information Officer & Senior Vice President of InterMune, Inc. He received an undergraduate degree from Brooklyn College and an MBA from Pace University.
Ed Gemo active positions
| Companies | Position | Start |
|---|---|---|
| TURG POIN | Chief Tech/Sci/R&D Officer | - |
Former positions of Ed Gemo
| Companies | Position | End |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2019-12-31 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Tech/Sci/R&D Officer | - |
| INTERMUNE INC | Chief Tech/Sci/R&D Officer | - |
Training of Ed Gemo
| Brooklyn College | Undergraduate Degree |
| Pace University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Ed Gemo
